Skip to main content

Menu

British National Formulary February 2024 Update

This update contains 7 significant changes, 5 new monographs, 2 new preparations, and 3 deleted monographs.

Significant Changes:

  • Bromocriptine: updated important safety information.
  • Controlled drugs and drug dependence: control of nitrous oxide.
  • Insulin degludec (Tresiba®): potential for inappropriate dosing of insulin when switching Tresiba® products [National Patient Safety Alert advice].
  • Liraglutide (Saxenda®): vigilance required due to potentially harmful falsified products [MHRA/CHM advice].
  • Nirmatrelvir with ritonavir (Paxlovid®): be alert to the risk of drug interactions with ritonavir [MHRA/CHM advice].
  • Semaglutide (Ozempic®): vigilance required due to potentially harmful falsified products [MHRA/CHM advice].
  • Valproate: organisations to prepare for new regulatory measures for oversight of prescribing to new patients and existing female patients [National Patient Safety Alert advice] (advice in sodium valproate, valproic acid; see example in sodium valproate).

New Monographs:

  • Columvi® [glofitamab].
  • Domnisol® [calcifediol monohydrate].
  • Nexpovio® [selinexor].
  • Slynd® [drospirenone].
  • Talvey® [talquetamab].

New Preparations: Octasa® MR 1600 mg tablets [mesalazine]; Octasa® suppositories [mesalazine].

Deleted Monographs: Diflucortolone valerate; Fluocinolone acetonide with clioquinol; Fluocinolone acetonide with neomycin.